Characteristics of the subcohort and the subsets based on asparaginase truncation and AEA
| Characteristics . | Subcohort . | TruncatedorAEA− . | Non-TruncatedandAEA+ . |
|---|---|---|---|
| No. of patients | 1115 | 301 (27.0) | 814 (73.0) |
| Age at diagnosis, y | |||
| Median [IQR] | 4 [2-7] | 4 [2-8] | 4 [2-7] |
| <10, no. (%) | 927 (83.1) | 244 (81.1) | 683 (83.9) |
| ≥10, no. (%) | 188 (16.9) | 57 (18.9) | 131 (16.1) |
| Sex, no. (%) | |||
| Male | 604 (54.2) | 164 (54.5) | 440 (54.1) |
| Female | 511 (45.8) | 137 (45.5) | 374 (45.9) |
| NOPHO risk group, no. (%) | |||
| SR | 671 (60.2) | 178 (59.1) | 493 (60.6) |
| IR | 444 (39.8) | 123 (40.9) | 321 (39.4) |
| NCI risk group, no. (%) | |||
| SR | 771 (69.1) | 207 (68.8) | 564 (69.3) |
| HR | 344 (30.9) | 94 (31.2) | 250 (30.7) |
| CNS status at diagnosis, no. (%) | |||
| CNS 1 | 980 (87.9) | 268 (89.0) | 712 (87.5) |
| CNS 2 | 86 (7.7) | 19 (6.3) | 67 (8.2) |
| CNS 3 | 47 (4.2) | 12 (4.0) | 35 (4.3) |
| Missing value | 2 (0.2) | 2 (0.7) | — (—) |
| MRD group, day 29, no. (%) | |||
| MRD 1 | 229 (20.5) | 72 (23.9) | 157 (19.3) |
| MRD 2 | 286 (25.7) | 70 (23.3) | 216 (26.5) |
| MRD 3 | 135 (12.1) | 38 (12.6) | 97 (11.9) |
| MRD 4 | 460 (41.3) | 119 (39.5) | 341 (41.9) |
| Missing value | 5 (0.4) | 2 (0.7) | 3 (0.4) |
| WBC at diagnosis, 109/L | |||
| Median [IQR] | 9.3 [4.4-31.9] | 9.4 [4.6-30.7] | 9.25 [4.3-32.1] |
| Asp. doses given* | |||
| Median [IQR] | 15 [8-15] | 6 [3-11] | 15 [8-15] |
| Characteristics . | Subcohort . | TruncatedorAEA− . | Non-TruncatedandAEA+ . |
|---|---|---|---|
| No. of patients | 1115 | 301 (27.0) | 814 (73.0) |
| Age at diagnosis, y | |||
| Median [IQR] | 4 [2-7] | 4 [2-8] | 4 [2-7] |
| <10, no. (%) | 927 (83.1) | 244 (81.1) | 683 (83.9) |
| ≥10, no. (%) | 188 (16.9) | 57 (18.9) | 131 (16.1) |
| Sex, no. (%) | |||
| Male | 604 (54.2) | 164 (54.5) | 440 (54.1) |
| Female | 511 (45.8) | 137 (45.5) | 374 (45.9) |
| NOPHO risk group, no. (%) | |||
| SR | 671 (60.2) | 178 (59.1) | 493 (60.6) |
| IR | 444 (39.8) | 123 (40.9) | 321 (39.4) |
| NCI risk group, no. (%) | |||
| SR | 771 (69.1) | 207 (68.8) | 564 (69.3) |
| HR | 344 (30.9) | 94 (31.2) | 250 (30.7) |
| CNS status at diagnosis, no. (%) | |||
| CNS 1 | 980 (87.9) | 268 (89.0) | 712 (87.5) |
| CNS 2 | 86 (7.7) | 19 (6.3) | 67 (8.2) |
| CNS 3 | 47 (4.2) | 12 (4.0) | 35 (4.3) |
| Missing value | 2 (0.2) | 2 (0.7) | — (—) |
| MRD group, day 29, no. (%) | |||
| MRD 1 | 229 (20.5) | 72 (23.9) | 157 (19.3) |
| MRD 2 | 286 (25.7) | 70 (23.3) | 216 (26.5) |
| MRD 3 | 135 (12.1) | 38 (12.6) | 97 (11.9) |
| MRD 4 | 460 (41.3) | 119 (39.5) | 341 (41.9) |
| Missing value | 5 (0.4) | 2 (0.7) | 3 (0.4) |
| WBC at diagnosis, 109/L | |||
| Median [IQR] | 9.3 [4.4-31.9] | 9.4 [4.6-30.7] | 9.25 [4.3-32.1] |
| Asp. doses given* | |||
| Median [IQR] | 15 [8-15] | 6 [3-11] | 15 [8-15] |
See Table 1 for expansion of abbreviations.
PEG-asparaginase doses including recalculated Erwinia asparaginase doses (6 doses of Erwinia asparaginase corresponds to 1 dose of PEG-asparaginase).